Zevra Therapeutics, Inc. (ZVRA) Return on equity 2021–2025
Zevra Therapeutics, Inc. (ZVRA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
53.8%FY2025 · since FY2021: -8.4% → 53.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 53.8% | +319.8 pp |
| FY2024 | -266.0% | -191.6 pp |
| FY2023 | -74.4% | -38.8 pp |
| FY2022 | -35.6% | -27.2 pp |
| FY2021 | -8.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ZVRA financial trends
ZVRA RevenueZVRA Net incomeZVRA Net marginZVRA Gross profitZVRA Gross marginZVRA Operating incomeZVRA Operating marginZVRA Operating cash flowZVRA Free cash flowZVRA Capital expendituresZVRA Stock buybacksZVRA Dividends paidZVRA Total assetsZVRA Total liabilitiesZVRA Shareholders’ equityZVRA overview →